Evidence map›Paper›PMID 41334126›Full record

ReviewGerms2025

Evolving insights into viral hepatitis: Advances, evidence, and expert perspectives from the ESCMID Study Group for Viral Hepatitis (ESGVH) - Part 1: hepatitis A, E, and herpesvirus-associated liver diseas.

Oana Săndulescu, Mojca Matičič, Federico Garcia, Marianne Alanko Blomé, Mario U Mondelli, William Irving, Snjezana Zidovec-Lepej, Anders Widell, Gülşen Özkaya Şahin, ESCMID Study Group for Viral Hepatitis (ESGVH)

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Germs, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Traveling with chronic viral hepatitis.Tropical diseases, travel medicine and vaccines · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Oana SăndulescuMD, PhD, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania, and National Institute for Infectious Diseases "Prof. Dr. Matei Balş", Bucharest 021105, Romania, and Academy of Romanian Scientists, Romania, and Infection Science Forum, and Chair of ESCMID Study Group for Viral Hepatitis (ESGVH) Executive Committee.
Mojca MatičičMD, PhD, Clinic for Infectious Diseases and Febrile Illnesses, University Medical Centre Ljubljana, and Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia, and ESCMID Study Group for Viral Hepatitis (ESGVH) Executive Committee.
Federico GarciaPharm D, PhD, Hospital Universitario Clínico San Cecilio, Granada 18016, Spain, and Instituto de Investigación ibs.GRANADA, Granada, Spain, and Centro de Investigación Biomédica en Red de Enfermedades Infecciosas - CIBERINFEC, Spain, and Former President of SEIMC, and ESCMID Study Group for Viral Hepatitis (ESGVH).
Marianne Alanko BloméMD, PhD, Department of Infectious Diseases, Skåne University Hospital, Malmö, Sweden, and Clinical Infection Medicine and Department of Translational Medicine, Lund University, Lund, Sweden, and Center for Communicable Disease Prevention and Control, Skåne Region, Sweden.
Mario U MondelliMD, PhD, Division of Clinical Immunology - Infectious Diseases, Fondazione IRCCS Policlinico San Matteo, and Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy, and ESCMID Study Group for Viral Hepatitis (ESGVH).
William IrvingFRCPath, PhD, NIHR Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust, University of Nottingham, Nottingham, UK and ESCMID Study Group for Viral Hepatitis (ESGVH).
Snjezana Zidovec-LepejPhD, Associate Professor, Department of Immunological and Molecular Diagnostics, University Hospital for Infectious Diseases "Dr. Fran Mihaljevic", Mirogojska, Zagreb, Croatia, and ESCMID Study Group for Viral Hepatitis (ESGVH).
Anders WidellMD, PhD, Associate Professor, Senior virologist, retired from clinical work, Department of Translational Medicine, Clinical Virology, Lund University, Lund University Virus Centre, Wallenberg laboratory, Malmö 214 28, Sweden.
Gülşen Özkaya ŞahinMD, PhD, Clinical Microbiology, Infection Prevention and Control, Office for Medical Services, Region Skåne, Lund, Sweden, and Division of Medical Microbiology, Department of Laboratory Medicine Lund, Medical Faculty, Lund University, Lund, Sweden, and ESCMID Study Group for Viral Hepatitis (ESGVH).
ESCMID Study Group for Viral Hepatitis (ESGVH)

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Viral hepatitis remains a global health concern, with growing recognition of the impact of hepatitis A virus (HAV), hepatitis E virus (HEV), and herpesvirus-associated hepatitis, particularly in vulnerable groups. This narrative review from the ESCMID Study Group for Viral Hepatitis (ESGVH) summarizes recent advances and expert perspectives. For HAV, insights into viral evolution, epidemiology, and risk groups underline the preventable nature of severe disease. HEV is increasingly recognized as both a hepatotropic and a systemic pathogen, with expanding knowledge on natural and vaccine-induced immunity. Herpesvirus-associated hepatitis, while rare, poses significant challenges, especially in patients with immunosuppression or during pregnancy, where early suspicion and empirical antiviral therapy can be lifesaving. Collectively, these evolving insights highlight the importance of strengthened diagnostics, targeted prevention, and tailored management strategies to mitigate the burden of these underappreciated but clinically significant causes of viral hepatitis.

Indexed as

HAVhepatitis Ahepatitis EherpesvirusHEVliverViral hepatitis

Identifiers

PMID41334126
PMCPMC12642957

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.